The treatment of advanced prostate cancer has evolved rapidly in the last 5 years. Therapeutic options for patients with advanced disease, once essentially limited to the use of androgen deprivation, have expanded to include a number of interventions, including secondary hormonal manipulations, ...
It's approved only for treatment of patients with few or no prostate cancer symptoms whose cancer has spread outside the prostate gland and is no longer responding to hormone therapy. Once a cancer grows beyond a certain point, the immune system has a hard time fighting it. One reason is ...
There is a dramatic revolution under way in the treatment of advanced-stage prostate cancer, which for many years consisted of systemic chemotherapy that offered only palliation of symptoms and no hope of improved survival. The last decade has witnessed the debut of a completely new arsenal of ...
Cite this: Degarelix 240/80 mg: A New Treatment Option for Patients with Advanced Prostate Cancer - Medscape - Dec 01, 2009.Recommendations Olaparib Combo Improves PFS in Metastatic Prostate Cancer news Small PFS Gain in Metastatic Prostate Cancer With TKI, ICI news Living With Cancer: Examin...
“This study reveals a critical mechanism behind treatment resistance in prostate cancer, suggesting new therapeutic approaches,” said Dr. Diaz-Meco. “By understanding EZH2’s role in this context, we may be able to re-sensitize tumors to androgen receptor inhibitors or make the cancer newly vu...
Modulation of the Activity of Sp Transcription Factors by Mithramycin Analogues as a New Strategy for Treatment of Metastatic Prostate Cancer Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. PLoS One 7, ......
In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.
Advanced prostate cancer treatment 专利名称：Advanced prostate cancer treatment 发明人：本間 之夫,藤村 哲也,井上 聡 申请号：JP2015170994 申请日：20150831 公开号：JP6586326B2 公开日：20191002 专利内容由知识产权出版社提供 摘要：PROBLEM TO BE SOLVED: To provide an agent for treating advanced prostate...
This scalable and cost-effective approach is also suitable for longitudinal monitoring and prediction of treatment-emergent prostate cancer resulting from therapeutic resistance.\nCitation Format: Navonil De Sarkar. Native Cell-Free DNA ... N Sarkar - 《Cancer Prevention Research》 被引量: 0发表: ...
High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options Article 24 April 2024 New Treatments for Recurrent Uterine Cancer Article 04 November 2021 Introduction Endometrial cancer (EC) is the most common gynecologic malignancy in the United States, with an estimated...